The cost effectiveness of newer epilepsy treatments: A review of the literature on partial-onset seizures

PharmacoEconomics

Volumn 30, Issue 10, 2012, Pages 903-923

  Bolin, Kristian ^a   Forsgren, Lars ^b  

^a LUND UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Antiepileptic drugs; Complex partial epilepsy; Cost effectiveness; Epilepsy; Gabapentin; Lacosamide; Lamotrigine; Levetiracetam; Partial epilepsies; Pregabalin; Rufinamide; Topiramate; Vigabatrin; Zonisamide.

Indexed keywords

ANTICONVULSIVE AGENT; CLOBAZAM; ESLICARBAZEPINE; ETIRACETAM; FELBAMATE; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PREGABALIN; RUFINAMIDE; TIAGABINE; TOPIRAMATE; VIGABATRIN; ZONISAMIDE;

ABSENTEEISM; ANTICONVULSANT THERAPY; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DISEASE CONTROL; DRUG COST; DRUG EFFICACY; DRUG MARKETING; EPILEPSY; HEALTH CARE COST; HEALTH STATUS; HUMAN; MONOTHERAPY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; QUALITY OF LIFE; SYSTEMATIC REVIEW;

ABSENTEEISM; ANTICONVULSANTS; COST-BENEFIT ANALYSIS; EPILEPSIES, PARTIAL; EUROPE; HUMANS; MODELS, ECONOMIC; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; RESEARCH DESIGN;

EID: 84866066555     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11597110-000000000-00000     Document Type: Article

References (57)

1. Forsgren L, Beghi E, Oun A, et al. The epidemiology of epilepsy in Europe: a systematic review. Eur J Neurol 2005; 12: 245-53 (Pubitemid 40477131)
2. Berg A, Bercovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51: 676-85
3. Liou HH, Chen RC, Chen CC, et al. Health related quality of life in adult patients with epilepsy compared with a general reference population in Taiwan. Epilepsy Res 2005; 64 (3): 151-9
4. Pugliatti M, Beghi E, Forsgren L, et al. Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 2007; 48: 2224-33 (Pubitemid 350243405)
5. Strzelczyk A, Reese JP, Dodel R, et al. Cost of epilepsy: a systematic review. Pharmacoeconomics 2008; 26 (6): 463-76 (Pubitemid 351704857)
6. Smeets VM, van Lierop BA, Vanhoutvin JP, et al. Epilepsy and employment: literature review. Epilepsy Behav 2007; 10 (3): 354-62 (Pubitemid 46567775)
7. Wilby J, Kainth A, Hawkins N, et al. Clinical effectiveness, tolerability and cost effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 2005; 9 (15): 1-157, iii-iv
8. Beghi E, Atzeni L, Garattini L. Economic analysis of newer antiepileptic drugs. CNS Drugs 2008; 22 (10): 861-75
9. Brodie M, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010; 75: 1817-24
10. Porter RJ, Partiot A, Sachdeo R, et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007; 68: 1197-204 (Pubitemid 46608467)
11. Chung S, Sperling M, Biton V, et al. Lacosamide: efficacy and safety as oral adjunctive treatment for partial-onset seizures. Neurology 2008; 70 Suppl. 1: 74-5
12. Halá sz P, Kä lviä inen R, Mazurkiewicz-Beldziń ska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50: 443-53
13. Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48: 1308-17 (Pubitemid 47063096)
14. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275-83 (Pubitemid 26254740)
15. Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006; 24 (4): 355-71
16. US Bureau of Labor Statistics. Consumer price index history table. Washington, DC: US Bureau of Labor Statistics, 2011
17. Statistics Canada, CANSIM. Consumer price index history table. Ottawa: Statistics Canada, 2011
18. Eurostat. Indices of consumer prices. Luxembourg: Eurostat, 2011
19. Office for National Statistics. Consumer price indices. Newport: Office for National Statistics, 2011
20. Heaney DC, Begley CE. Economic evaluation of epilepsy treatment: a review of the literature. Epilepsia 2002; 43 Suppl. 4: 10-6 (Pubitemid 34627710)
21. Levy P. Economic evaluation of antiepileptic drug therapy: a methodologic review. Epilepsia 2002; 43 (5): 550-8 (Pubitemid 34533713)
22. Connock M, Frew E, Evans BW, et al. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy: a systematic review. Health Technol Assess 2006; 10 (7): iii, ix-118
23. Simoens S. Pharmacoeconomics of anti-epileptic drugs as adjunctive therapy for refractory epilepsy. Expert Rev Pharmacoecon Outcomes Res 2010; 10 (3): 309-15
24. Benedict A, Verdian L, Maclaine G. The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK [published erratum appears in Pharmacoeconomics 2011; 29 (12): 1014]. Pharmacoeconomics 2010; 28 (3): 185-99
25. Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures: cost utility results for Sweden. Acta Neurol Scand 2010; 121 (6): 406-12
26. Verdian L, Yi Y. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom. Seizure 2010; 19 (1): 1-11
27. Suh GH, Lee SK. Economic evaluation of add-on levetiracetam for the treatment of refractory partial epilepsy in Korea. Psychiatry Investig 2009; 6 (3): 185-93
28. Vera-Llonch M, Brandenburg NA, Oster G. Costeffectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy. Epilepsia 2008; 49 (3): 431-7 (Pubitemid 351294524)
29. Frew EJ, Sandercock J, Whitehouse WP, et al. The costeffectiveness of newer drugs as add-on therapy for children with focal epilepsies. Seizure 2007; 16: 99-112 (Pubitemid 46222210)
30. Spackman D, Yeates A, Rentz A, et al. The cost effectiveness of zonisamide as adjunctive therapy in adult partial seizure epilepsy. J Med Econ 2007; 10: 455-73
31. Blais L, Sheehy O, St-Hilaire JM, et al. Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy. Pharmacoeconomics 2005; 23 (5): 493-503 (Pubitemid 40994137)
32. Knoester PD, Boendermaker AJ, Egberts AC, et al. Costeffectiveness of add-on lamotrigine therapy in clinical practice. Epilepsy Res 2005; 67 (3): 143-51 (Pubitemid 41676823)
33. Remák E, Hutton J, Selai CE, et al. A cost-utility analysis of adjunctive treatment with newer antiepileptic drugs in the UK. J Med Econ 2004; 7: 29-40 (Pubitemid 38931751)
34. Maltoni S, Messori A. Lifetime cost-utility analysis of patients with refractory epilepsy treated with adjunctive topiramate therapy: cost-effectiveness in refractory epilepsy. Clin Drug Investig 2003; 23 (4): 225-32 (Pubitemid 36469960)
35. Remák E, Hutton J, Price M, et al. A Markov model of treatment of newly diagnosed epilepsy in the UK: an initial assessment of cost-effectiveness of topiramate. Eur J Health Econ 2003; 4 (4): 271-8 (Pubitemid 38081990)
36. Selai CE, Smith K, Trimble MR. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs. Seizure 1999; 8 (1): 8-13 (Pubitemid 29117001)
37. Heaney DC, Shorvon SD, Sander JW. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia 1998; 39 (3): S19-25 (Pubitemid 28215211)
38. Markowitz MA, Mauskopf JA, Halpern MT. Costeffectiveness model of adjunctive lamotrigine for the treatment of epilepsy. Neurology 1998; 51 (4): 1026-33 (Pubitemid 28473395)
39. Messori A, Trippoli S, Becagli P, et al. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol 1998; 53 (6): 421-7 (Pubitemid 28154742)
40. Shakespeare A, Simeon G. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK. Seizure 1998; 7: 119-25 (Pubitemid 28226936)
41. Hughes D, Cockerell OC. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy. Seizure 1996; 5 (2): 89-95 (Pubitemid 126687051)
42. O'Neill BA, Trimble MR, Bloom DS. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options. Seizure 1995; 4 (1): 37-44
43. Sculpher M, Pang F, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess 2004; 8 (49): iii-iv, 1-192
44. Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force Report. Value Health 2009; 12 (4): 409-18
45. Appleby J, Devlin N, Parkin D, et al. Searching for cost effectiveness thresholds in the NHS. Health Policy 2009; 91: 239-45
46. Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010; 19: 422-37
47. Bobinac A, van Exel NJ, Rutten FF, et al. Willingness to pay for a quality-adjusted life-year: the individual perspective. Value Health 2010; 13 (8): 1046-55
48. Kenkel D. WTP-and QALY-based approaches to valuing health for policy: common ground and disputed territory. Environ Resour Econ 2006; 34: 419-37
49. Caro JJ, Nord E, Siebert U, et al. The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ 2010; 19 (10): 1117-27
50. Ivanova JI, Birnbaum HG, Kidolezi Y, et al. Economic burden of epilepsy among the privately insured in the US. Pharmacoeconomics 2010; 28 (8): 675-85
51. Ivanova JI, Birnbaum HG, Kidolezi Y, et al. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States. Epilepsia 2010; 51 (5): 838-44
52. Meltzer D. Accounting for future costs in medical costeffectiveness analysis. J Health Econ 1997; 16: 33-64 (Pubitemid 27224093)
53. Lundin D, Ramsberg J. On survival consumption costs: a reply to Nyman. Health Econ 2008; 17: 293-7 (Pubitemid 351266001)
54. Nyman JA. Should the consumption of survivors be included as a cost in cost-utility analysis? Health Econ 2004; 13: 417-27 (Pubitemid 38660391)
55. Nyman JA. More on survival consumption costs in costutility analysis. Health Econ 2006; 15: 319-22 (Pubitemid 43349354)
56. Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 2010; 28 (10): 935-45
57. Russell LB, Gold MR, Siegel JE, et al. The role of costeffectiveness analysis in health and medicine. JAMA 1996; 276 (14): 1172-7 (Pubitemid 26329746)